GW Pharma’s latest clinical trial successful, stock soars

British cannabis company GW Pharmaceuticals has conducted a successful clinical trial in which it treated epileptic children with one of its marijuana-based drugs, triggering a surge in the company’s stock price.

According to Reuters, tested doses of GW Pharmaceutical’s drug Epidiolex “were found to have induced a statistically significant improvement in reducing seizures” in patients with a particular type of epilepsy during phase III clinical trials.

On Monday, after news of the trials broke, the publicly traded company’s stock shot up 16% to a record high of 811 pence on the London Stock Exchange, Reuters reported. The news agency has said the company is a possible takeover target.

The next step for GW Pharmaceuticals is approval by the U.S. Food and Drug Administration. The company plans to submit a marketing application for Epidiolex to the agency during the first half of next year.

If Epidiolex is approved, according to Reuters, it could become the first U.S.-approved drug extracted from marijuana.

GW Pharmaceuticals’ stock fell from its highs Tuesday on the Nasdaq, closing down $1.15 at $124.91.

6 comments on “GW Pharma’s latest clinical trial successful, stock soars
    • Lawrence Goodwin on

      I believe the sleazy phrase used in Schedule I of the federal Controlled Substances Act is “no currently accepted medical use.” It’s extremely strange that law still applies, especially considering how the feds have been growing cannabis at the University of Mississippi for decades and supplying medical “marihuana” to a handful of qualified patients; or the critical 2003 patent #6,630,057 filed by the U.S. Department of Health and Human Services, titled, “Cannabinoids as Antioxidants and Neuroprotectants.” No matter what federal law says, rock solid evidence from 4,000 years of female cannabis flowers being utilized effectively as medicine (including over the course of almost 100 years in the United States) can never be nullified.

      Reply
  1. Michelle DeMello on

    How Can our Government FDA approve a medicine with Hemp in it when it has Hemp as a Schedule 1drug saying that it has no medical benefit?
    Why are our USA citizens punished while they approve a drug from England. NOt right.

    Reply
  2. Hastings RH on

    GWPH has huge upside so a position still makes sense..

    Our FDA is a corrupt monopoly in cahoots with big pharma -that’s why we pay 3 times more per capita than Canada and 5 times more than England and France. We pay 6 times more for an epipen -pretty disgusting -hopefully Trump wins and breaks up the robber baron cabal a la Teddy Roosevelt

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *